NCT05136677CompletedPhase 2
A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
A Phase II, Randomized, Open-label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First-line Therapy for Unresectable Pleural Mesothelioma in Chinese Participants
Source: ClinicalTrials.gov · Last updated 23 Jan 2026
Brief summary (registry, in English)
The purpose of this study is to assess the efficacy and safety of the combination of nivolumab and ipilimumab in Chinese participants with malignant pleural mesothelioma.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 102 (actual)
- First submitted
- 18 Nov 2021
- Start date
- 25 Jan 2022
- Primary completion date
- 12 Nov 2025
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Mesothelioma, Lung cancer
- NCT number
- NCT05136677
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 102
- From 25 Jan 2022 to the primary completion date, 12 Nov 2025
- 21 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Brain metastasis, except if surgically resected or treated with stereotaxic radiotherapy
- Prior therapy for MPM (including chemotherapy, radical pleuropneumonectomy and non-palliative radiotherapy)
- Other protocol-defined inclusion/exclusion criteria apply
Other
- Primitive peritoneal, pericardial, testis or tunica vaginalis mesothelioma
Who the study is looking for
- Histologically proven diagnosis of Malignant Pleural Mesothelioma (MPM) with determination of epithelioid vs non-epithelioid histology
- Must have advanced unresectable disease that is not amenable to therapy with curative intent (surgery with or without chemotherapy)
- Available tumor samples for centralized testing
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1
- Measurable disease
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (21)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.